PharmaShots | Incisive News in 3 Shots

Subscribe Now

second anti-cancer compound

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following the US FDA's Acceptance of IND for P-I Study of XL114 in Non-Hodgkin's Lymphoma

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following the US FDA's Acceptance of IND for P-I Study of XL114 in...

October 15, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us